Disease · EFO_0000195
metabolic syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. metabolic syndrome. Diseases, record EFO_0000195. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0000195
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Cardiovascular Syndrome, Metabolic, Cardiovascular Syndromes, Metabolic, Dysmetabolic Syndrome X, Insulin Resistance Syndrome X, MetS, Metabolic Cardiovascular Syndrome, Metabolic Syndrome X, Metabolic X Syndrome, Reaven Syndrome X, Syndrome X, Dysmetabolic, Syndrome X, Insulin Resistance, Syndrome X, Metabolic, Syndrome X, Reaven, Syndrome, Metabolic Cardiovascular, Syndrome, Metabolic X, X Syndrome, Metabolic
- Open Targets
Drugs108
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 20 | 20 | Drugs and targets |
| EZETIMIBE | CHEMBL1138 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BERBERINE | CHEMBL295124 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TELMISARTAN | CHEMBL1017 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 108
See all 108 drugsTargets172
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 7 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 6 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptors; D2 & D3 antagonist | Unknown | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 6 | Serotonin (5-HT) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | Unknown | https://conductscience.org/library/genes/3356 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 5 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 4 | Gonadotropin-releasing hormone receptor agonist | Phase 2 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 4 | Serotonin (5-HT) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | Unknown | https://conductscience.org/library/genes/3358 | Drugs and targets |
| AR | Androgen receptor | 3 | Androgen Receptor agonist; Androgen Receptor antagonist | Phase 3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| DRD3 | D2-like dopamine receptor | 3 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine receptors; D2 & D3 antagonist | Unknown | https://conductscience.org/library/genes/1814 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 3 | Mineralocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| PGR | Progesterone receptor | 3 | Progesterone receptor agonist; Progesterone receptor antagonist | Phase 3 | https://conductscience.org/library/genes/5241 | Drugs and targets |
1 to 10 of 172
See all 172 targetsTrials117
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00546052 | A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331) | Phase 3 | 1,738 | 2009-06-23 | Hypertension, Metabolic Disorder | HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00455403 | Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS) | Not applicable | 357 | 2021-06-25 | Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State | CHLOROQUINE | Its record names the disease | ClinicalTrials.gov |
| NCT02503865 | Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome | Phase 1/2 | 351 | 2015-11-03 | Metabolic Syndrome | ATORVASTATIN, ORLISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00496730 | A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED) | Phase 3 | 256 | 2009-11-17 | Hypercholesterolemia | EZETIMIBE, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03229057 | Comparing the Effects of Oral Contraceptive Pills Versus Metformin | Phase 3 | 240 | 2025-03-10 | PCOS | DESOGESTREL, ETHINYL ESTRADIOL, METFORMIN | Its record names the disease | ClinicalTrials.gov |
| NCT02878798 | Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN) | Phase 2 | 132 | 2023-11-14 | Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT01700530 | Exercise, Statins, and the Metabolic Syndrome | Not applicable | 121 | 2016-02-05 | Metabolic Syndrome, Obese, Sedentary | SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT01785615 | Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin | Phase 1/2 | 116 | 2017-06-07 | Metabolic Syndrome | ATORVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00442689 | Metabolic Syndrome in PCOS: Precursors and Interventions | Not applicable | 97 | 2014-06-06 | Polycystic Ovary Syndrome, Metabolic Syndrome | DROSPIRENONE, ETHINYL ESTRADIOL, FLUTAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00105066 | The Effects of Metformin on Blood Vessel Structure and Function | Phase 2 | 77 | 2017-01-18 | Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia | METFORMIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 117
See all 117 trialsComparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Topiramate vs Placebo: deaths from any cause | 0 of 66 | 0 of 66 | 132 | NCT02878798 | Trial comparisons |
| Topiramate vs Placebo: serious adverse events | 4 of 66 | 9 of 66 | 132 | NCT02878798 | Trial comparisons |
| Chloroquine Subjects vs Placebo Subjects: deaths from any cause | 0 of 59 | 0 of 57 | 116 | NCT00455403 | Trial comparisons |
| Chloroquine Subjects vs Placebo Subjects: serious adverse events | 5 of 59 | 2 of 57 | 116 | NCT00455403 | Trial comparisons |
| Atorvastatin vs Sugar Pill: serious adverse events | 0 of 44 | 0 of 44 | 88 | NCT01785615 | Trial comparisons |
| Acipimox vs Placebo: deaths from any cause | 0 of 40 | 0 of 40 | 80 | NCT00759291 | Trial comparisons |
| Acipimox vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT00759291 | Trial comparisons |
| Pioglitazone Placebo + Open-Label Niacin + Aspirin vs Active Pioglitazone + Open-Label Niacin + Asprin: serious adverse events | 3 of 38 | 2 of 40 | 78 | NCT00300365 | Trial comparisons |
| Metformin vs Placebo: serious adverse events | 0 of 50 | 0 of 27 | 77 | NCT00105066 | Trial comparisons |
| Diet Intervention vs GLP-1 Intervention: deaths from any cause | 0 of 17 | 0 of 38 | 55 | NCT03919929 | Trial comparisons |
1 to 10 of 34
See all 34 comparisons in its trialsPapers from its trials107
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0000195
GET https://conductscience.org/api/diseases/v1/EFO_0000195/drugs?page=2